Boehringer Ingelheim Vetmedica Inc. Enters Into an Agreement to Sell U.S. Feline, Canine and Rabies Vaccines Portfolio to Elanco Animal Health

Deal Subject to FTC Approval and Successful Closing of BI/Sanofi Asset Swap

Boehringer Ingelheim Vetmedica Inc. (BIVI) today announced an agreement with Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), to sell a portfolio of U.S. canine, feline and rabies vaccines, as well as a fully integrated manufacturing and R&D site, to Elanco. The sale price of $885 million includes the estimated cost of acquired inventory. The deal is conditioned on antitrust approval and closing of the Boehringer Ingelheim (BI) asset swap transaction with Sanofi that was signed in June 2016.

“This agreement is an important step toward a successful acquisition of Merial,” said Dr. Albrecht Kissel, president and CEO of Boehringer Ingelheim Vetmedica Inc. “This was a highly complex decision from a business and from an emotional perspective. It was certainly not taken lightly particularly in view of the history and significant positive developments of this business over the past years.”

do you see the similarities here,,, Elanco bought the team, the lab and the IP ,,,